Company Analysis Artiva Biotherapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (123.74%) is higher than the sector average (-5.48%).
- Current debt level 6.85% is below 100% and has decreased over 5 years from 7.25%.
Disadvantages
- Price (4.18 $) is higher than fair price (3.72 $)
- Dividends (0%) are below the sector average (0%).
- The company's current efficiency (ROE=-475.05%) is lower than the sector average (ROE=385.88%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Artiva Biotherapeutics, Inc. | Index | ||
|---|---|---|---|
| 7 days | 3% | 0% | 1.4% |
| 90 days | -18.1% | 0.7% | 3% |
| 1 year | 123.7% | -5.5% | 21.2% |
ARTV vs Sector: Artiva Biotherapeutics, Inc. has outperformed the "" sector by 129.22% over the past year.
ARTV vs Market: Artiva Biotherapeutics, Inc. has outperformed the market by 102.57% over the past year.
Stable price: ARTV is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ARTV with weekly volatility of 2.38% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (4.18 $) is higher than the fair price (3.72 $).
Price is higher than fair: The current price (4.18 $) is 11% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-0.5294) is lower than that of the sector as a whole (40.3).
P/E vs Market: The company's P/E (-0.5294) is higher than that of the market as a whole (-68.72).
5.3. P/BV
P/BV vs Sector: The company's P/BV (0.6081) is higher than that of the sector as a whole (-2038.46).
P/BV vs Market: The company's P/BV (0.6081) is lower than that of the market as a whole (51.39).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (452.15) is higher than that of the sector as a whole (29.32).
P/S vs Market: The company's P/S indicator (452.15) is higher than that of the market as a whole (148.63).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.35) is higher than that of the sector as a whole (-870.14).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.35) is higher than that of the market as a whole (-95.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -3.71% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-3.71%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-59.39%).
6.4. ROE
ROE vs Sector: The company's ROE (-475.05%) is lower than that of the sector as a whole (385.88%).
ROE vs Market: The company's ROE (-475.05%) is lower than that of the market as a whole (-6.23%).
6.6. ROA
ROA vs Sector: The company's ROA (-37.17%) is higher than that of the sector as a whole (-51.45%).
ROA vs Market: The company's ROA (-37.17%) is lower than that of the market as a whole (38.59%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.66%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
